Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2002 | 03-2002 | 12-2001 | 09-2001 | 06-2001 | |
| Sales | 31,831 | 27,404 | 29,295 | 25,277 | 25,372 |
| Cost of Goods | 11,681 | 10,647 | 6,813 | 9,783 | 9,696 |
| Gross Profit | 20,150 | 16,757 | 22,482 | 15,494 | 15,676 |
| Operating Expenses | 6,032 | 5,323 | 9,989 | 4,870 | 4,607 |
| Operating Income | 14,799 | 12,081 | 13,306 | 11,407 | 11,765 |
| Other Income | 1,773 | 1,686 | 1,049 | 1,892 | 2,301 |
| Pre-tax Income | 16,572 | 13,767 | 14,355 | 13,299 | 14,066 |
| Income Tax | 6,013 | 4,999 | 5,101 | 4,819 | 5,198 |
| Net Income Continuous | 10,559 | 8,768 | 9,254 | 8,480 | 8,868 |
| Net Income | $10,559 | $8,768 | $9,254 | $8,480 | $8,868 |
| EPS Basic Total Ops | 0.32 | 0.26 | 0.27 | 0.26 | 0.27 |
| EPS Basic Continuous Ops | 0.32 | 0.26 | 0.28 | 0.26 | 0.27 |
| EPS Diluted Total Ops | 0.32 | 0.26 | 0.27 | 0.25 | 0.26 |
| EPS Diluted Continuous Ops | 0.32 | 0.26 | 0.27 | 0.25 | 0.26 |
| EBITDA(a) | $16,086 | $13,019 | $14,611 | $12,857 | $13,099 |